JOHNSON & JOHNSON
JNJAPI behind this page
JNJ Q1 2026 request
Playground key active
/api/financials?ticker=JNJ&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 24,062 | 21,893 | +9.9% |
Show Product Lines breakouts |
|||
| ADVANCED · MEDTECH | 477 | 457 | +4.4% |
| ADVANCED · MEDTECH | 646 | 616 | +4.9% |
| ADVANCED · MEDTECH | 1,123 | 1,073 | +4.7% |
| CAPLYTA · Innovative Medicine | 270 | — | — |
| CAPLYTA · Innovative Medicine | 270 | — | — |
| CARVYKTI · Innovative Medicine | 433 | 318 | +36.2% |
| CARVYKTI · Innovative Medicine | 164 | 51 | +221.6% |
| CARVYKTI · Innovative Medicine | 597 | 369 | +61.8% |
| CONCERTA/Methylphenidate · Innovative Medicine | 22 | 38 | -42.1% |
| CONCERTA/Methylphenidate · Innovative Medicine | 115 | 110 | +4.5% |
| CONCERTA/Methylphenidate · Innovative Medicine | 136 | 148 | -8.1% |
| CONTACT LENSES / OTHER · MEDTECH | 468 | 452 | +3.5% |
| CONTACT LENSES / OTHER · MEDTECH | 501 | 467 | +7.3% |
| CONTACT LENSES / OTHER · MEDTECH | 969 | 919 | +5.4% |
| DARZALEX · Innovative Medicine | 2,208 | 1,829 | +20.7% |
| DARZALEX · Innovative Medicine | 1,756 | 1,409 | +24.6% |
| DARZALEX · Innovative Medicine | 3,964 | 3,237 | +22.5% |
| EDURANT/rilpivirine · Innovative Medicine | 7 | 8 | -12.5% |
| EDURANT/rilpivirine · Innovative Medicine | 402 | 350 | +14.9% |
| EDURANT/rilpivirine · Innovative Medicine | 409 | 358 | +14.2% |
| ERLEADA · Innovative Medicine | 342 | 292 | +17.1% |
| ERLEADA · Innovative Medicine | 607 | 479 | +26.7% |
| ERLEADA · Innovative Medicine | 949 | 771 | +23.1% |
| GENERAL · MEDTECH | 569 | 544 | +4.6% |
| GENERAL · MEDTECH | 819 | 778 | +5.3% |
| GENERAL · MEDTECH | 1,388 | 1,323 | +4.9% |
| HIPS · MEDTECH | 277 | 263 | +5.3% |
| HIPS · MEDTECH | 159 | 146 | +8.9% |
| HIPS · MEDTECH | 436 | 409 | +6.6% |
| IMBRUVICA · Innovative Medicine | 143 | 235 | -39.1% |
| IMBRUVICA · Innovative Medicine | 517 | 474 | +9.1% |
| IMBRUVICA · Innovative Medicine | 660 | 709 | -6.9% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 758 | 625 | +21.3% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 280 | 277 | +1.1% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 1,038 | 903 | +15.0% |
| KNEES · MEDTECH | 239 | 231 | +3.5% |
| KNEES · MEDTECH | 181 | 158 | +14.6% |
| KNEES · MEDTECH | 420 | 389 | +8.0% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 433 | 363 | +19.3% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 172 | 159 | +8.2% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 606 | 522 | +16.1% |
| OTHER IMMUNOLOGY · Innovative Medicine | 38 | 1 | +3700.0% |
| OTHER IMMUNOLOGY · Innovative Medicine | 9 | 0 | — |
| OTHER IMMUNOLOGY · Innovative Medicine | 46 | 1 | +4500.0% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 1 | 2 | -50.0% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 36 | 39 | -7.7% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 37 | 41 | -9.8% |
| OTHER NEUROSCIENCE · Innovative Medicine | 38 | 28 | +35.7% |
| OTHER NEUROSCIENCE · Innovative Medicine | 224 | 248 | -9.7% |
| OTHER NEUROSCIENCE · Innovative Medicine | 262 | 277 | -5.4% |
| Other Oncology · Innovative Medicine | 85 | 54 | +57.4% |
| Other Oncology · Innovative Medicine | 106 | 160 | -33.8% |
| Other Oncology · Innovative Medicine | 192 | 214 | -10.3% |
| Other · Innovative Medicine | 91 | 165 | -44.8% |
| Other · Innovative Medicine | 12 | 15 | -20.0% |
| Other · Innovative Medicine | 1,907 | 1,914 | -0.4% |
| Other · Innovative Medicine | 142 | 158 | -10.1% |
| Other · Innovative Medicine | 34 | 37 | -8.1% |
| Other · Innovative Medicine | 993 | 926 | +7.2% |
| Other · Innovative Medicine | 233 | 323 | -27.9% |
| Other · Innovative Medicine | 46 | 52 | -11.5% |
| Other · Innovative Medicine | 2,899 | 2,840 | +2.1% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 334 | 305 | +9.5% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 109 | 98 | +11.2% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 443 | 403 | +9.9% |
| Remicade · Innovative Medicine | 269 | 314 | -14.3% |
| Remicade · Innovative Medicine | 18 | 10 | +80.0% |
| Remicade · Innovative Medicine | 136 | 143 | -4.9% |
| Remicade · Innovative Medicine | 422 | 467 | -9.6% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 175 | 113 | +54.9% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 82 | 28 | +192.9% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 257 | 141 | +82.3% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 269 | 292 | -7.9% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 378 | 366 | +3.3% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 647 | 659 | -1.8% |
| SPINE & OTHER · MEDTECH | 387 | 388 | -0.3% |
| SPINE & OTHER · MEDTECH | 307 | 283 | +8.5% |
| SPINE & OTHER · MEDTECH | 694 | 671 | +3.4% |
| SPRAVATO · Innovative Medicine | 406 | 276 | +47.1% |
| SPRAVATO · Innovative Medicine | 61 | 43 | +41.9% |
| SPRAVATO · Innovative Medicine | 468 | 320 | +46.2% |
| STELARA · Innovative Medicine | 220 | 981 | -77.6% |
| STELARA · Innovative Medicine | 435 | 644 | -32.5% |
| STELARA · Innovative Medicine | 656 | 1,625 | -59.6% |
| SURGICAL · MEDTECH | 111 | 114 | -2.6% |
| SURGICAL · MEDTECH | 285 | 246 | +15.9% |
| SURGICAL · MEDTECH | 396 | 361 | +9.7% |
| TALVEY · Innovative Medicine | 101 | 68 | +48.5% |
| TALVEY · Innovative Medicine | 51 | 18 | +183.3% |
| TALVEY · Innovative Medicine | 152 | 86 | +76.7% |
| Tecvayli · Innovative Medicine | 127 | 105 | +21.0% |
| Tecvayli · Innovative Medicine | 74 | 46 | +60.9% |
| Tecvayli · Innovative Medicine | 202 | 151 | +33.8% |
| TRAUMA · MEDTECH | 532 | 502 | +6.0% |
| TRAUMA · MEDTECH | 301 | 270 | +11.5% |
| TRAUMA · MEDTECH | 833 | 772 | +7.9% |
| Tremfya · Innovative Medicine | 1,042 | 599 | +74.0% |
| Tremfya · Innovative Medicine | 566 | 356 | +59.0% |
| Tremfya · Innovative Medicine | 1,608 | 956 | +68.2% |
| UPTRAVI · Innovative Medicine | 385 | 365 | +5.5% |
| UPTRAVI · Innovative Medicine | 98 | 86 | +14.0% |
| UPTRAVI · Innovative Medicine | 483 | 451 | +7.1% |
| XARELTO · Innovative Medicine | 642 | 690 | -7.0% |
| XARELTO · Innovative Medicine | 642 | 690 | -7.0% |
Show Business Segments breakouts |
|||
| Innovative Medicine | 15,426 | 13,873 | +11.2% |
| Innovative Medicine · Cardiovascular / Metabolism / Other | 876 | 1,013 | -13.5% |
| Innovative Medicine · Immunology | 3,380 | 3,707 | -8.8% |
| Innovative Medicine · Infectious Diseases | 889 | 802 | +10.8% |
| Innovative Medicine · Neuroscience | 2,175 | 1,647 | +32.1% |
| Innovative Medicine · Non Us | 6,555 | 5,781 | +13.4% |
| Innovative Medicine · Non Us | 142 | 158 | -10.1% |
| Innovative Medicine · Non Us | 1,524 | 1,510 | +0.9% |
| Innovative Medicine · Non Us | 547 | 487 | +12.3% |
| Innovative Medicine · Non Us | 681 | 679 | +0.3% |
| Innovative Medicine · Non Us | 3,358 | 2,664 | +26.1% |
| Innovative Medicine · Non Us | 304 | 281 | +8.2% |
| Innovative Medicine · Oncology | 6,973 | 5,678 | +22.8% |
| Innovative Medicine · Operating Segments | 15,426 | 13,873 | +11.2% |
| Innovative Medicine · Pulmonary Hypertension | 1,135 | 1,025 | +10.7% |
| Innovative Medicine · US | 8,871 | 8,092 | +9.6% |
| Innovative Medicine · US | 734 | 855 | -14.2% |
| Innovative Medicine · US | 1,855 | 2,196 | -15.5% |
| Innovative Medicine · US | 342 | 315 | +8.6% |
| Innovative Medicine · US | 1,494 | 968 | +54.3% |
| Innovative Medicine · US | 3,615 | 3,013 | +20.0% |
| Innovative Medicine · US | 831 | 744 | +11.7% |
| MEDTECH | 8,636 | 8,020 | +7.7% |
| MEDTECH · ABIOMED | 488 | 420 | +16.2% |
| MEDTECH · Cardiovascular [Member] | 2,377 | 2,103 | +13.0% |
| MEDTECH · ELECTROPHYSIOLOGY | 1,489 | 1,323 | +12.5% |
| MEDTECH · Non Us | 4,177 | 3,807 | +9.7% |
| MEDTECH · Non Us | 100 | 81 | +23.5% |
| MEDTECH · Non Us | 978 | 842 | +16.2% |
| MEDTECH · Non Us | 753 | 638 | +18.0% |
| MEDTECH · Non Us | 948 | 857 | +10.6% |
| MEDTECH · Non Us | 62 | 72 | -13.9% |
| MEDTECH · Non Us | 63 | 52 | +21.2% |
| MEDTECH · Non Us | 1,465 | 1,394 | +5.1% |
| MEDTECH · Non Us | 785 | 713 | +10.1% |
| MEDTECH · Operating Segments | 8,636 | 8,020 | +7.7% |
| MEDTECH · Orthopaedics | 2,383 | 2,241 | +6.3% |
| MEDTECH · Other Cardiovascular | 94 | 103 | -8.7% |
| MEDTECH · Shockwave | 305 | 258 | +18.2% |
| MEDTECH · Surgery | 2,511 | 2,396 | +4.8% |
| MEDTECH · US | 4,459 | 4,213 | +5.8% |
| MEDTECH · US | 389 | 339 | +14.7% |
| MEDTECH · US | 1,399 | 1,261 | +10.9% |
| MEDTECH · US | 736 | 684 | +7.6% |
| MEDTECH · US | 1,435 | 1,384 | +3.7% |
| MEDTECH · US | 32 | 32 | 0.0% |
| MEDTECH · US | 242 | 206 | +17.5% |
| MEDTECH · US | 1,046 | 1,002 | +4.4% |
| MEDTECH · US | 579 | 566 | +2.3% |
| MEDTECH · Vision | 1,365 | 1,279 | +6.7% |
Show Geography breakouts |
|||
| Asia-Pacific, Africa | 3,591 | 3,311 | +8.5% |
| Europe | 5,848 | 5,110 | +14.4% |
| Non Us | 10,732 | 9,588 | +11.9% |
| US | 13,330 | 12,305 | +8.3% |
| Western Hemisphere, excluding U.S. | 1,293 | 1,167 | +10.8% |
| Sales Revenue Goods Net Percent To Sales | 100 | 100 | 0.0% |
| Cost of Revenue | 8,106 | 7,357 | +10.2% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 4,390 | 4,020 | +9.2% |
| MEDTECH · Operating Segments | 3,701 | 3,326 | +11.3% |
| Cost Of Goods Sold Percent To Sales | 33.7 | 33.6 | +0.3% |
| Gross Profit | 15,956 | 14,536 | +9.8% |
| Gross Profit Percent To Sales | 66.3 | 66.4 | -0.2% |
| Selling, General & Administrative | 6,034 | 5,112 | +18.0% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 2,918 | 2,261 | +29.1% |
| MEDTECH · Operating Segments | 2,906 | 2,656 | +9.4% |
| Selling General And Administrative Expense Percent To Sales | 25.1 | 23.3 | +7.7% |
| Research And Development Expense Excluding Acquired In Process Cost | 3,527 | 3,225 | +9.4% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 2,813 | 2,548 | +10.4% |
| MEDTECH · Operating Segments | 714 | 677 | +5.5% |
| Research And Development Expense Excluding Acquired In Process Cost Percent To Sales | 14.7 | 14.7 | 0.0% |
| Research And Development In Process1 | 36 | — | — |
| Research And Development In Process Percent To Sales | 0.1 | — | — |
| Interest Income | -229 | -332 | +31.0% |
| Investment Income Interest Percent To Sales | -1 | -1.5 | +33.3% |
| Interest Expense | 272 | 204 | +33.3% |
| Interest Expense Percent To Sales | 1.2 | 0.9 | +33.3% |
| Other Non-Operating Income (Expense) | 294 | -7,321 | +104.0% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 12 | 166 | -92.8% |
| MEDTECH · Operating Segments | -76 | 60 | -226.7% |
| Other Non Operating Income Expense Percent To Sales | 1.2 | -33.4 | +103.6% |
| Restructuring Charges | 32 | 17 | +88.2% |
Show Business Segments breakouts |
|||
| MedTech Surgery Franchise · Costs of Goods and Services Sold | 20 | — | — |
| MedTech Surgery Franchise · Operating Segments | 55 | — | — |
| MedTech Surgery Franchise · Other (income) expense | 5 | — | — |
| MedTech Surgery Franchise · Restructuring Charges | 30 | — | — |
| MEDTECH · Operating Segments | 7 | 55 | -87.3% |
| MEDTECH · Separation Related Costs | 0.1 | — | — |
Show Consolidation Items breakouts |
|||
| Operating Segments | 62 | 55 | +12.7% |
| Restructuringchargepercenttosales | 0.1 | 0.1 | 0.0% |
| Income Before Taxes | 5,990 | 13,631 | -56.1% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 5,317 | 5,210 | +2.1% |
| MEDTECH · Operating Segments | 1,239 | 1,421 | -12.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 6,556 | 6,631 | -1.1% |
| Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest Percent To Sales | 24.9 | 62.3 | -60.0% |
| Income Tax Expense (Benefit) | 755 | 2,632 | -71.3% |
| Income Tax Expense Benefit Percent To Sales | 3.1 | 12.1 | -74.4% |
| Income Loss From Continuing Operations Net Of Tax Attributable To Parent Percent Of Sales | 21.8 | 50.2 | -56.6% |
| Net Income | 5,235 | 10,999 | -52.4% |
Show Equity Components breakouts |
|||
| Retained Earnings | 5,235 | 10,999 | -52.4% |
| EPS (Basic) | 2.17 | 4.57 | -52.5% |
| EPS (Diluted) | 2.14 | 4.54 | -52.9% |
| Wtd Avg Shares (Basic) | 2,408.7 | 2,407.2 | +0.1% |
| Wtd Avg Shares (Diluted) | 2,445.2 | 2,423.8 | +0.9% |
| Comprehensive Income | 5,334 | 11,000 | -51.5% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -77 | 676 | -111.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 21,688 | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Money Market Funds | 5,089 | — | — |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 6,312 | — | — |
| Availableforsale Securities · Corporate Debt Securities | 29 | — | — |
| Availableforsale Securities · Sovereign Debt Securities | 76 | — | — |
| Availableforsale Securities · US Treasury And Government | 6,207 | — | — |
| Heldtomaturity Securities | 15,376 | — | — |
| Heldtomaturity Securities · Bank Time Deposits | 724 | — | — |
| Heldtomaturity Securities · Cash | 3,310 | — | — |
| Heldtomaturity Securities · Money Market Funds | 5,089 | — | — |
| Heldtomaturity Securities · Securities Loaned Or Sold Under Agreements To Repurchase | 6,253 | — | — |
| Marketable Securities (Current) | 363 | 307 | +18.2% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 363 | 307 | +18.2% |
| Availableforsale Securities · Corporate Debt Securities | 187 | 178 | +5.1% |
| Availableforsale Securities · Sovereign Debt Securities | 158 | 116 | +36.2% |
| Availableforsale Securities · US Treasury And Government | 18 | 13 | +38.5% |
| Accounts Receivable | 17,721 | 16,020 | +10.6% |
| Inventory | 14,583 | 12,659 | +15.2% |
| Prepaid Expenses & Other Current Assets | 4,818 | 4,091 | +17.8% |
| Total Current Assets | 59,173 | 71,551 | -17.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 23,270 | 20,871 | +11.5% |
| Goodwill | 48,558 | — | — |
Show Business Segments breakouts |
|||
| Innovative Medicine | 14,812 | — | — |
| MEDTECH | 33,746 | — | — |
| Deferred Tax Assets | 6,727 | 8,492 | -20.8% |
| Other Non-Current Assets | 14,105 | 11,534 | +22.3% |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 703 | 471 | +49.3% |
| Equity Securities · Equity Investments without readily determinable value | 888 | 787 | +12.8% |
| Total Assets | 200,894 | 193,671 | +3.7% |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 36,597 | 49,833 | -26.6% |
| Innovative Medicine · Operating Segments | 78,118 | 58,727 | +33.0% |
| MEDTECH · Operating Segments | 86,179 | 85,111 | +1.3% |
| Segments Total | 164,297 | 143,838 | +14.2% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 6,184 | 6,611 | -6.5% |
| Patents And Trademarks | 25,576 | 17,843 | +43.3% |
| Marketable Securities (Non-Current) (Q) | — | — | — |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 703 | 471 | +49.3% |
| Other Assets | |||
| Property Plant And Equipment Gross | 54,695 | 49,884 | +9.6% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | -31,425 | -29,013 | -8.3% |
| Intangible Assets Net Excluding Goodwill | 49,061 | 36,755 | +33.5% |
| Current Liabilities | |||
| Short Term Borrowings | 17,460 | 13,897 | +25.6% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 17,460 | 13,897 | +25.6% |
| Estimate Of Fair Value Fair Value Disclosure | 17,455 | 13,855 | +26.0% |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 15.7 | 10.9 | +44.0% |
| Accounts Payable | 10,460 | 9,545 | +9.6% |
| Accrued Liabilities | 7,399 | 7,913 | -6.5% |
| Accrued Rebates Returns And Promotions | 18,399 | 18,780 | -2.0% |
| Employee Related Liabilities Current | 2,911 | 2,551 | +14.1% |
| Accrued Income Taxes Current | 1,087 | 4,217 | -74.2% |
| Total Current Liabilities | 57,716 | 56,903 | +1.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 37,527 | 38,355 | -2.2% |
Show Debt Instrument breakouts |
|||
| 0.95% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 1,499 | 1,479 | +1.4% |
| 0.95% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 1,439 | 1,395 | +3.2% |
| 1.150% Notes due 2028 (750MM Euro 1.1541) · Carrying Reported Amount Fair Value Disclosure | 863 | 806 | +7.1% |
| 1.150% Notes due 2028 (750MM Euro 1.1541) · Estimate Of Fair Value Fair Value Disclosure | 826 | 772 | +7.0% |
| 1.30% Notes due 2030 · Carrying Reported Amount Fair Value Disclosure | 1,702 | 1,672 | +1.8% |
| 1.30% Notes due 2030 · Estimate Of Fair Value Fair Value Disclosure | 1,544 | 1,499 | +3.0% |
| 1.650% Notes due 2035 (1.5B Euro 1.1541) · Carrying Reported Amount Fair Value Disclosure | 1,722 | 1,607 | +7.2% |
| 1.650% Notes due 2035 (1.5B Euro 1.1541) · Estimate Of Fair Value Fair Value Disclosure | 1,463 | 1,393 | +5.0% |
| 2.10% Notes due 2040 · Carrying Reported Amount Fair Value Disclosure | 902 | 874 | +3.2% |
| 2.10% Notes due 2040 · Estimate Of Fair Value Fair Value Disclosure | 687 | 689 | -0.3% |
| 2.25% Notes due 2050 · Carrying Reported Amount Fair Value Disclosure | 864 | 837 | +3.2% |
| 2.25% Notes due 2050 · Estimate Of Fair Value Fair Value Disclosure | 572 | 582 | -1.7% |
| 2.45% Notes due 2060 · Carrying Reported Amount Fair Value Disclosure | 1,118 | 1,088 | +2.8% |
| 2.45% Notes due 2060 · Estimate Of Fair Value Fair Value Disclosure | 660 | 694 | -4.9% |
| 2.700% Notes Due February 2029 · Carrying Reported Amount Fair Value Disclosure | 692 | 646 | +7.1% |
| 2.700% Notes Due February 2029 · Estimate Of Fair Value Fair Value Disclosure | 685 | 648 | +5.7% |
| 2.90% Notes due 2028 · Carrying Reported Amount Fair Value Disclosure | 1,499 | 1,498 | +0.1% |
| 2.90% Notes due 2028 · Estimate Of Fair Value Fair Value Disclosure | 1,470 | 1,452 | +1.2% |
| 3.050% Notes Due February 2033 · Carrying Reported Amount Fair Value Disclosure | 806 | 752 | +7.2% |
| 3.050% Notes Due February 2033 · Estimate Of Fair Value Fair Value Disclosure | 786 | 749 | +4.9% |
| 3.20% Notes due 2032 (700MM Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 805 | 752 | +7.0% |
| 3.20% Notes due 2032 (700MM Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 798 | 762 | +4.7% |
| 3.35% Notes Due 2036 (800MM Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 919 | 858 | +7.1% |
| 3.35% Notes Due 2036 (800MM Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 892 | 849 | +5.1% |
| 3.350% Notes Due February 2037 · Carrying Reported Amount Fair Value Disclosure | 1,151 | 1,075 | +7.1% |
| 3.350% Notes Due February 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,100 | 1,058 | +4.0% |
| 3.40% Notes due 2038 · Carrying Reported Amount Fair Value Disclosure | 994 | 993 | +0.1% |
| 3.40% Notes due 2038 · Estimate Of Fair Value Fair Value Disclosure | 855 | 855 | 0.0% |
| 3.50% Notes due 2048 · Carrying Reported Amount Fair Value Disclosure | 744 | 744 | 0.0% |
| 3.50% Notes due 2048 · Estimate Of Fair Value Fair Value Disclosure | 555 | 569 | -2.5% |
| 3.55% Notes Due 2044 (1.0B Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 1,144 | 1,068 | +7.1% |
| 3.55% Notes Due 2044 (1.0B Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 1,057 | 1,037 | +1.9% |
| 3.587% Notes due 2036 · Carrying Reported Amount Fair Value Disclosure | 925 | 897 | +3.1% |
| 3.587% Notes due 2036 · Estimate Of Fair Value Fair Value Disclosure | 903 | 894 | +1.0% |
| 3.600% Notes Due February 2045 · Carrying Reported Amount Fair Value Disclosure | 802 | 749 | +7.1% |
| 3.600% Notes Due February 2045 · Estimate Of Fair Value Fair Value Disclosure | 741 | 723 | +2.5% |
| 3.625% Notes due 2037 · Carrying Reported Amount Fair Value Disclosure | 1,414 | 1,387 | +1.9% |
| 3.625% Notes due 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,333 | 1,333 | 0.0% |
| 3.700% Notes Due February 2055 · Carrying Reported Amount Fair Value Disclosure | 1,148 | 1,072 | +7.1% |
| 3.700% Notes Due February 2055 · Estimate Of Fair Value Fair Value Disclosure | 1,027 | 1,020 | +0.7% |
| 3.73% Notes due 2046 · Carrying Reported Amount Fair Value Disclosure | 1,980 | 1,979 | +0.1% |
| 3.73% Notes due 2046 · Estimate Of Fair Value Fair Value Disclosure | 1,565 | 1,604 | -2.4% |
| 3.75% Notes due 2047 · Carrying Reported Amount Fair Value Disclosure | 877 | 852 | +2.9% |
| 3.75% Notes due 2047 · Estimate Of Fair Value Fair Value Disclosure | 778 | 802 | -3.0% |
| 4.375% Notes due 2033 · Carrying Reported Amount Fair Value Disclosure | 853 | 854 | -0.1% |
| 4.375% Notes due 2033 · Estimate Of Fair Value Fair Value Disclosure | 845 | 838 | +0.8% |
| 4.50% Notes due 2040 · Carrying Reported Amount Fair Value Disclosure | 542 | 542 | 0.0% |
| 4.50% Notes due 2040 · Estimate Of Fair Value Fair Value Disclosure | 512 | 524 | -2.3% |
| 4.50% Notes due 2043 · Carrying Reported Amount Fair Value Disclosure | 497 | 496 | +0.2% |
| 4.50% Notes due 2043 · Estimate Of Fair Value Fair Value Disclosure | 453 | 464 | -2.4% |
| 4.55% Notes Due 2029 · Carrying Reported Amount Fair Value Disclosure | 749 | 748 | +0.1% |
| 4.55% Notes Due 2029 · Estimate Of Fair Value Fair Value Disclosure | 758 | 758 | 0.0% |
| 4.70% Notes due 2030 · Carrying Reported Amount Fair Value Disclosure | 996 | 995 | +0.1% |
| 4.70% Notes due 2030 · Estimate Of Fair Value Fair Value Disclosure | 1,018 | 1,017 | +0.1% |
| 4.80% Notes due 2029 · Carrying Reported Amount Fair Value Disclosure | 1,147 | 1,146 | +0.1% |
| 4.80% Notes due 2029 · Estimate Of Fair Value Fair Value Disclosure | 1,174 | 1,175 | -0.1% |
| 4.85% Notes Due 2032 · Carrying Reported Amount Fair Value Disclosure | 1,243 | 1,242 | +0.1% |
| 4.85% Notes Due 2032 · Estimate Of Fair Value Fair Value Disclosure | 1,275 | 1,268 | +0.6% |
| 4.85% Notes due 2041 · Carrying Reported Amount Fair Value Disclosure | 298 | 298 | 0.0% |
| 4.85% Notes due 2041 · Estimate Of Fair Value Fair Value Disclosure | 292 | 293 | -0.3% |
| 4.90% Notes due 2031 · Carrying Reported Amount Fair Value Disclosure | 1,146 | 1,146 | 0.0% |
| 4.90% Notes due 2031 · Estimate Of Fair Value Fair Value Disclosure | 1,180 | 1,178 | +0.2% |
| 4.95% Notes due 2033 · Carrying Reported Amount Fair Value Disclosure | 499 | 499 | 0.0% |
| 4.95% Notes due 2033 · Estimate Of Fair Value Fair Value Disclosure | 518 | 514 | +0.8% |
| 4.95% Notes due 2034 · Carrying Reported Amount Fair Value Disclosure | 847 | 846 | +0.1% |
| 4.95% Notes due 2034 · Estimate Of Fair Value Fair Value Disclosure | 882 | 870 | +1.4% |
| 5.00% Notes due 2035 · Carrying Reported Amount Fair Value Disclosure | 1,244 | 1,243 | +0.1% |
| 5.00% Notes due 2035 · Estimate Of Fair Value Fair Value Disclosure | 1,275 | 1,270 | +0.4% |
| 5.25% Notes due 2054 · Carrying Reported Amount Fair Value Disclosure | 843 | 843 | 0.0% |
| 5.25% Notes due 2054 · Estimate Of Fair Value Fair Value Disclosure | 831 | 850 | -2.2% |
| 5.85% Notes due 2038 · Carrying Reported Amount Fair Value Disclosure | 697 | 697 | 0.0% |
| 5.85% Notes due 2038 · Estimate Of Fair Value Fair Value Disclosure | 754 | 760 | -0.8% |
| 5.95% Notes due 2037 · Carrying Reported Amount Fair Value Disclosure | 995 | 994 | +0.1% |
| 5.95% Notes due 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,085 | 1,094 | -0.8% |
| 6.95% Notes due 2029 · Carrying Reported Amount Fair Value Disclosure | 299 | 299 | 0.0% |
| 6.95% Notes due 2029 · Estimate Of Fair Value Fair Value Disclosure | 327 | 334 | -2.1% |
| Other · Carrying Reported Amount Fair Value Disclosure | 62 | 83 | -25.3% |
| Other · Estimate Of Fair Value Fair Value Disclosure | 77 | 83 | -7.2% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 37,527 | 38,355 | -2.2% |
| Estimate Of Fair Value Fair Value Disclosure | 34,992 | 36,406 | -3.9% |
| Deferred Tax Liabilities | 7,011 | 2,428 | +188.8% |
| Employee Related Liabilities Current And Noncurrent | 6,760 | 7,046 | -4.1% |
| Accrued Income Taxes Noncurrent | 486 | 395 | +23.0% |
| Other Non-Current Liabilities | 10,208 | 10,435 | -2.2% |
| Total Liabilities | 119,708 | 115,562 | +3.6% |
| Stockholders' Equity | |||
| Common Stock | 3,120 | 3,120 | 0.0% |
| Accumulated Other Comprehensive Income | -14,831 | -11,740 | -26.3% |
| Retained Earnings | 169,161 | 162,635 | +4.0% |
| Treasury Stock Common Value | 76,264 | 75,906 | +0.5% |
| Total Stockholders' Equity | 81,186 | 78,109 | +3.9% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 81,186 | 78,109 | +3.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -654 | -1,509 | +56.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -564 | -1,216 | +53.6% |
| Accumulated Other Comprehensive Income | -14,831 | -11,740 | -26.3% |
| Accumulated Translation Adjustment | -13,613 | -9,016 | -51.0% |
| Common Stock | 3,120 | 3,120 | 0.0% |
| Retained Earnings | 169,161 | 162,635 | +4.0% |
| Treasury Stock Common | -76,264 | -75,906 | -0.5% |
| Total Liabilities & Equity | 200,894 | 193,671 | +3.7% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 2,004 | 1,772 | +13.1% |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 65 | 52 | +25.0% |
| Innovative Medicine · Operating Segments | 1,036 | 884 | +17.2% |
| MEDTECH · Operating Segments | 903 | 836 | +8.0% |
| Segments Total | 1,939 | 1,720 | +12.7% |
| Stock-Based Compensation | 300 | 288 | +4.2% |
| Asset Impairment Charges | 36 | 30 | +20.0% |
| In Process Research And Development Charge | 2 | 16 | -87.5% |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | 12 | -75 | +116.0% |
| Deferred Income Taxes | 159 | 2,172 | -92.7% |
| Provision For Doubtful Accounts | -8 | -4 | -100.0% |
| Change in Accounts Receivable | -595 | -926 | +35.7% |
| Change in Inventory | -431 | -146 | -195.2% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -3,920 | -2,126 | -84.4% |
| Increase Decrease In Other Operating Assets | 349 | -1,317 | +126.5% |
| Increase Decrease In Other Operating Liabilities | -629 | -6,509 | +90.3% |
| Net Cash from Operations | 2,514 | 4,174 | -39.8% |
| Investing Activities | |||
| Capital Expenditures | -1,049 | -795 | -31.9% |
| Proceeds From Sale Of Productive Assets | 29 | 279 | -89.6% |
| Payments To Acquire Investments | -144 | -251 | +42.6% |
| Proceeds From Sale Maturity And Collections Of Investments | 209 | 218 | -4.1% |
| Proceeds Payments From To Credit Support Agreements Investing Activities | -31 | 296 | -110.5% |
| Other Investing Activities | -54 | -30 | -80.0% |
| Net Cash from Investing | -1,040 | -297 | -250.2% |
| Financing Activities | |||
| Payments Of Ordinary Dividends | -3,131 | -2,989 | -4.8% |
| Share Repurchases | -4,028 | -2,127 | -89.4% |
| Proceeds From Short Term Debt | 12,439 | 8,784 | +41.6% |
| Repayments Of Short Term Debt | -3,223 | -2,120 | -52.0% |
| Repayments Of Senior Debt | -2,002 | -751 | -166.6% |
| Proceeds From Exercise Of Stock Options And Excess Tax Benefits | 1,172 | 450 | +160.4% |
| Proceeds Payments From To Credit Support Agreements Financing Activities | -109 | -3 | -3533.3% |
| Proceeds From Payments For Other Financing Activities | -588 | 40 | -1570.0% |
| Net Cash from Financing | 530 | 10,422 | -94.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -25 | 70 | -135.7% |
| Net Change in Cash | 1,979 | 14,369 | -86.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 21,688 | 38,474 | -43.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.